166 related articles for article (PubMed ID: 15846457)
21. Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions.
Covitz KM; Amidon GL; Sadée W
Biochemistry; 1998 Oct; 37(43):15214-21. PubMed ID: 9790685
[TBL] [Abstract][Full Text] [Related]
22. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter.
Song X; Vig BS; Lorenzi PL; Drach JC; Townsend LB; Amidon GL
J Med Chem; 2005 Feb; 48(4):1274-7. PubMed ID: 15715497
[TBL] [Abstract][Full Text] [Related]
23. Evidence for overlapping substrate specificity between large neutral amino acid (LNAA) and dipeptide (hPEPT1) transporters for PD 158473, an NMDA antagonist.
Surendran N; Covitz KM; Han H; Sadee W; Oh DM; Amidon GL; Williamson RM; Bigge CF; Stewart BH
Pharm Res; 1999 Mar; 16(3):391-5. PubMed ID: 10213369
[TBL] [Abstract][Full Text] [Related]
24. Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs.
Omkvist DH; Trangbæk DJ; Mildon J; Paine JS; Brodin B; Begtrup M; Nielsen CU
Eur J Pharm Biopharm; 2011 Feb; 77(2):327-31. PubMed ID: 21147219
[TBL] [Abstract][Full Text] [Related]
25. Conformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: implications for design of hPEPT1 targeted prodrugs.
Våbenø J; Nielsen CU; Steffansen B; Lejon T; Sylte I; Jørgensen FS; Luthman K
Bioorg Med Chem; 2005 Mar; 13(6):1977-88. PubMed ID: 15727852
[TBL] [Abstract][Full Text] [Related]
26. Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
Pedretti A; De Luca L; Marconi C; Regazzoni L; Aldini G; Vistoli G
Bioorg Med Chem; 2011 Aug; 19(15):4544-51. PubMed ID: 21741846
[TBL] [Abstract][Full Text] [Related]
27. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
28. Application of enzymatically stable dipeptides for enhancement of intestinal permeability. Synthesis and in vitro evaluation of dipeptide-coupled compounds.
Friedrichsen GM; Jakobsen P; Taub M; Begtrup M
Bioorg Med Chem; 2001 Oct; 9(10):2625-32. PubMed ID: 11557350
[TBL] [Abstract][Full Text] [Related]
29. QSAR models for the human H(+)/peptide symporter, hPEPT1: affinity prediction using alignment-independent descriptors.
Larsen SB; Jørgensen FS; Olsen L
J Chem Inf Model; 2008 Jan; 48(1):233-41. PubMed ID: 18092768
[TBL] [Abstract][Full Text] [Related]
30. In vitro evaluation of N-methyl amide tripeptidomimetics as substrates for the human intestinal di-/tri-peptide transporter hPEPT1.
Andersen R; Nielsen CU; Begtrup M; Jørgensen FS; Brodin B; Frokjaer S; Steffansen B
Eur J Pharm Sci; 2006 Jul; 28(4):325-35. PubMed ID: 16713701
[TBL] [Abstract][Full Text] [Related]
31. In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity.
Greupink R; Nabuurs SB; Zarzycka B; Verweij V; Monshouwer M; Huisman MT; Russel FG
Toxicol Sci; 2012 Sep; 129(1):35-48. PubMed ID: 22641618
[TBL] [Abstract][Full Text] [Related]
32. Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1.
Colas C; Masuda M; Sugio K; Miyauchi S; Hu Y; Smith DE; Schlessinger A
Mol Pharm; 2017 Dec; 14(12):4685-4693. PubMed ID: 29111754
[TBL] [Abstract][Full Text] [Related]
33. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
Krovat EM; Langer T
J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
[TBL] [Abstract][Full Text] [Related]
34. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa.
Krovat EM; Frühwirth KH; Langer T
J Chem Inf Model; 2005; 45(1):146-59. PubMed ID: 15667140
[TBL] [Abstract][Full Text] [Related]
35. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
36. Molecular identification of a role for tyrosine 167 in the function of the human intestinal proton- coupled dipeptide transporter (hPepT1).
Yeung AK; Basu SK; Wu SK; Chu C; Okamoto CT; Hamm-Alvarez SF; von Grafenstein H; Shen WC; Kim KJ; Bolger MB; Haworth IS; Ann DK; Lee VH
Biochem Biophys Res Commun; 1998 Sep; 250(1):103-7. PubMed ID: 9735340
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel serotonin 2C receptor ligands by sequential virtual screening.
Ahmed A; Choo H; Cho YS; Park WK; Pae AN
Bioorg Med Chem; 2009 Jul; 17(13):4559-68. PubMed ID: 19464901
[TBL] [Abstract][Full Text] [Related]
38. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity.
Nakanishi T; Tamai I; Takaki A; Tsuji A
Int J Cancer; 2000 Oct; 88(2):274-80. PubMed ID: 11004680
[TBL] [Abstract][Full Text] [Related]
39. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
40. Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations.
Våbenø J; Lejon T; Nielsen CU; Steffansen B; Chen W; Ouyang H; Borchardt RT; Luthman K
J Med Chem; 2004 Feb; 47(4):1060-9. PubMed ID: 14761208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
